PUBLISHER: TechNavio | PRODUCT CODE: 2172575
PUBLISHER: TechNavio | PRODUCT CODE: 2172575
Cancer Therapies Market In Europe 2026-2030
The cancer therapies market in europe is forecasted to grow by USD 31247.1 mn during 2025-2030, accelerating at a CAGR of 6.5% during the forecast period. The report on the cancer therapies market in europe provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing cancer burden across aging population base, advancing precision medicine adoption supported by biomarker-guided treatment selection, growing investment in oncology drug research and clinical development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 6.5% |
| CAGR | 6.5% |
| Incremental Value | $31247.1 mn |
Technavio's cancer therapies market in europe is segmented as below:
By Type
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Others
By Indication
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Others
By End-User
- Hospitals
- Specialty clinics
- Others
Geography
- Europe
- Germany
- UK
- France
- Italy
This study identifies the expanding use of AI-enabled platforms in oncology discovery and treatment planning as one of the prime reasons driving the cancer therapies market in europe growth during the next few years. Also, increasing shift toward combination therapy development strategies and evolving integration of real-world evidence into oncology treatment evaluation will lead to sizable demand in the market.
The report on the cancer therapies market in europe covers the following areas:
- Cancer therapies market in europe sizing
- Cancer therapies market in europe forecast
- Cancer therapies market in europe industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer therapies market in europe vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Incyte Corp., Ipsen Pharma, Jazz Pharmaceuticals Plc, Johnson and Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Ltd.. Also, the cancer therapies market in europe analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Country Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Indication
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Cancer Therapies Market in Europe 2020 - 2024
- Historic Market Size - Data Table on Cancer Therapies Market in Europe 2020 - 2024 ($ million)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.3 Indication segment analysis 2020 - 2024
- Historic Market Size - Indication Segment 2020 - 2024 ($ million)
- 5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on cancer therapies market in Europe
- 6.2 Impact of geopolitical conflicts on cancer therapies market in Europe
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 Chemotherapy - Market size and forecast 2025-2030
- 8.4 Targeted therapy - Market size and forecast 2025-2030
- 8.5 Immunotherapy - Market size and forecast 2025-2030
- 8.6 Others - Market size and forecast 2025-2030
- 8.7 Market opportunity by Type
- Market opportunity by Type ($ million)
9 Market Segmentation by Indication
- 9.1 Market segments
- 9.2 Comparison by Indication
- 9.3 Breast cancer - Market size and forecast 2025-2030
- 9.4 Lung cancer - Market size and forecast 2025-2030
- 9.5 Colorectal cancer - Market size and forecast 2025-2030
- 9.6 Prostate cancer - Market size and forecast 2025-2030
- 9.7 Others - Market size and forecast 2025-2030
- 9.8 Market opportunity by Indication
- Market opportunity by Indication ($ million)
10 Market Segmentation by End-user
- 10.1 Market segments
- 10.2 Comparison by End-user
- 10.3 Hospitals - Market size and forecast 2025-2030
- 10.4 Specialty clinics - Market size and forecast 2025-2030
- 10.5 Others - Market size and forecast 2025-2030
- 10.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 Germany - Market size and forecast 2025-2030
- 12.4 UK - Market size and forecast 2025-2030
- 12.5 France - Market size and forecast 2025-2030
- 12.6 Italy - Market size and forecast 2025-2030
- 12.7 Rest of Europe - Market size and forecast 2025-2030
- 12.8 Market opportunity by geography
- Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Increasing cancer burden across aging population base
- Advancing precision medicine adoption supported by biomarker-guided treatment selection
- Growing investment in oncology drug research and clinical development
- 13.2 Market challenges
- High clinical development failure rates in oncology pipelines
- Stringent reimbursement and health technology assessment requirements across Europe
- Manufacturing complexity for advanced biologic and cell-based therapies
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Expanding use of AI-enabled platforms in oncology discovery and treatment planning
- Increasing shift toward combination therapy development strategies
- Evolving integration of real-world evidence into oncology treatment evaluation
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.6 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 15.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.8 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- SWOT
- 15.9 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.10 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Business segments
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- Gilead Sciences Inc. - Segment focus
- SWOT
- 15.11 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.12 Ipsen Pharma
- Ipsen Pharma - Overview
- Ipsen Pharma - Business segments
- Ipsen Pharma - Key offerings
- Ipsen Pharma - Segment focus
- SWOT
- 15.13 Jazz Pharmaceuticals Plc
- Jazz Pharmaceuticals Plc - Overview
- Jazz Pharmaceuticals Plc - Product / Service
- Jazz Pharmaceuticals Plc - Key news
- Jazz Pharmaceuticals Plc - Key offerings
- SWOT
- 15.14 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 15.15 Merck KGaA
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key news
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- SWOT
- 15.16 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.17 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.18 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
